3 results
To determine the rate of detection of sub-clinical atrial AF (* 5 minutes) within an average of 12 months following implant of the Confirm® Implantable Cardiac Monitor in patients with known cardiovascular risk factors and left atrial enlargement,…
PRIMARY: Dose finding part (Phase 1):To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the recommended Phase 2 doses (RP2Ds) of each…
Objectives:The main objective will be to assess whether treatment with nVNS, LXB or both interventions will increase the clearance of Aβ from the brain, compared to pre-treatment, in patients with CAA. Second objective is to study whether CAA…